Advertisement
Canada markets closed
  • S&P/TSX

    22,465.37
    +165.57 (+0.74%)
     
  • S&P 500

    5,303.27
    +6.17 (+0.12%)
     
  • DOW

    40,003.59
    +134.19 (+0.34%)
     
  • CAD/USD

    0.7343
    -0.0005 (-0.06%)
     
  • CRUDE OIL

    79.75
    -0.31 (-0.39%)
     
  • Bitcoin CAD

    91,416.01
    -94.96 (-0.10%)
     
  • CMC Crypto 200

    1,372.31
    +17.90 (+1.32%)
     
  • GOLD FUTURES

    2,434.10
    +16.70 (+0.69%)
     
  • RUSSELL 2000

    2,095.72
    -0.53 (-0.03%)
     
  • 10-Yr Bond

    4.4200
    +0.0430 (+0.98%)
     
  • NASDAQ

    16,685.97
    -12.33 (-0.07%)
     
  • VOLATILITY

    12.19
    +0.20 (+1.67%)
     
  • FTSE

    8,440.70
    +20.44 (+0.24%)
     
  • NIKKEI 225

    39,069.68
    +282.30 (+0.73%)
     
  • CAD/EUR

    0.6756
    +0.0001 (+0.01%)
     

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Autolus Therapeutics plc
Autolus Therapeutics plc

LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights before open of US markets on Tuesday, May 14, 2024.

Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

ADVERTISEMENT

Contact:

Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com

Julia Wilson
+44 (0) 7818 430877 
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303 
susan@sanoonan.com